A large observational study found the increased risk associated with dual antiplatelet therapy cessation after percutaneous coronary intervention (PCI) is tied to patient non-adherence, as opposed to physician-recommended discontinuation. Results of the PARIS registry were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
